-
About NORMA Group
Company information
Strategy
Corporate Responsibility
-
-
Investor Relations
Management and Corporate GovernanceSharePublications and EventsOnline ReportsFinancial FiguresCreditor RelationsAGMServicesManagement and Corporate Governance
Share
Publications and Events
Online Reports
Financial Figures
Creditor Relations
AGM
Services
- Career
- Blog
- Contact us
-
Menu
- Industries
- Products
- Brands
-
About NORMA Group
Company information
Strategy
Corporate Responsibility
-
-
Investor Relations
Management and Corporate GovernanceSharePublications and EventsOnline ReportsFinancial FiguresCreditor RelationsAGMServicesManagement and Corporate Governance
Share
Publications and Events
Online Reports
Financial Figures
Creditor Relations
AGM
Services
- Career
- Blog
- Contact us
NORMA Group AG acquires Connectors Verbindungstechnik AG, a supplier to the pharmaceutical industry
Maintal, Germany, 19 April 2012
NORMA Group AG ("NORMA Group"), a global market and technology leader for engineered joining technology, acquired Connectors Verbindungstechnik AG ("Connectors") effective 19 April 2012. The parties agreed to maintain confidentiality on the details of the transaction.
Connectors, based in Tagelswangen, Switzerland, specialises on connector systems for the pharmaceutical and biotechnology industry. For more than 25 years, the company has been manufacturing and distributing connector elements that meet the highest purity standards for medical sterile technology. The product range includes clamps, valves, tubes and joining solutions for the transport of fluids and gases in medical applications. In addition, Connectors also offers its customers consultancy and planning services for pharmaceutical process plants. The company generated sales of around EUR 14 million in the financial year 2011. It will be consolidated as part of NORMA Group with immediate effect.
Werner Deggim, CEO of NORMA Group, says: "With the acquisition of this provider of specialised joining technology for medical engineering NORMA Group will get better access to customers in the pharmaceutical and biotechnology sectors. We will make use of the expertise of Connectors to extend our product portfolio and will improve our global leadership in joining technology even further."